Title of article :
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
Author/Authors :
Jose Valdez Madruga، نويسنده , , Daniel Berger، نويسنده , , Marilyn McMurchie، نويسنده , , Fredy Suter، نويسنده , , Denes Banhegyi، نويسنده , , Kiat Ruxrungtham، نويسنده , , Dorece Norris، نويسنده , , Eric Lefebvre، نويسنده , , Marie-Pierre de Bethune، نويسنده , , Frank Tomaka، نويسنده , , Martine De Pauw، نويسنده , , Tony Vangeneugden، نويسنده , , Sabrina Spinosa-Guzman، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
10
From page :
49
To page :
58
Abstract :
Background The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but needs to be assessed in patients with a broader range of treatment experience. We did a randomised, controlled, p
Journal title :
The Lancet
Serial Year :
2008
Journal title :
The Lancet
Record number :
591591
Link To Document :
https://search.isc.ac/dl/search/defaultta.aspx?DTC=10&DC=591591
بازگشت